A client filling in her medical history before a lip filler appointment lists one new medicine: a small tablet, taken each morning with her coffee, started six weeks ago. Until this year that line would almost always have described a weekly injection pen. Now it increasingly describes Foundayo (orforglipron), the once-daily tablet from Eli Lilly that UK pharmacies began dispensing on private prescription in August 2026. For anyone considering it, or trying to make sense of it before a visit to an aesthetic clinic, the useful questions are practical: what it is, how it is taken, what the first months feel like, how it compares with injections and what it costs. This guide answers each one using the UK licence and the published trial data.
UK Eli Lilly Foundayo Approval for Orforglipron Explained
The Medicines and Healthcare products Regulatory Agency authorised orforglipron on 10 August 2026, making the UK the first country in Europe to approve it. Anyone still asking Is Foundayo approved in the UK? now has a definite answer, with two licensed uses.
The first is weight management. Foundayo is licensed for adults with a body mass index (BMI) of 30 or above, or a BMI of 27 to under 30 with at least one weight-related condition such as prediabetes, type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea or heart disease. It is meant to sit alongside a reduced-calorie diet and more physical activity, not replace them.
The second is type 2 diabetes, where it improves blood sugar control, either on its own or with other diabetes medicines.
Foundayo is a prescription-only medicine and is not yet available on the NHS. NICE is appraising orforglipron for overweight and obesity, with its decision expected on 18 November 2026. Until then, anyone tracking Foundayo UK access will find the route is private only: a consultation, approval by a prescriber and dispensing by a registered pharmacy.
How the Foundayo Tablet Works in the Body
Orforglipron belongs to the same broad family as semaglutide and tirzepatide. It is a GLP-1 receptor agonist, meaning it switches on the receptor for glucagon-like peptide-1, a hormone the gut releases after eating. That receptor does three things that matter here:
- In the parts of the brain that regulate appetite, it reduces hunger and the urge to keep eating.
- In the pancreas, it increases insulin release, but only when blood sugar is raised. This is why low blood sugar is uncommon unless insulin or a sulfonylurea is also being taken.
- In the stomach, it slows emptying, so food stays longer and fullness lasts. The Foundayo 14.5 mg film-coated tablets SmPC notes this effect is strongest after the very first dose and fades over time.
Where orforglipron differs is its structure. Semaglutide and tirzepatide are peptides, chains of amino acids that the stomach would normally break down. Orforglipron is a small, non-peptide molecule, much closer to a conventional tablet medicine. That is why the UK licence allows it to be taken at any time of day, with no food or water restrictions.
This is the clearest practical difference between the Foundayo pill and the oral semaglutide tablet licensed in June 2026, which has to be taken on an empty stomach with a small sip of water and a wait before breakfast. For people with irregular mornings, shift patterns or several other medicines to take, that difference matters.
Body composition scans in the main weight trial showed the weight lost came mostly from fat, including visceral fat stored around the organs. Some lean mass was lost too, as happens with any significant weight loss, which is one reason diet quality and strength exercise still count.
Foundayo Tablets: Doses From 0.8 mg to 17.2 mg
Six strengths are licensed in the UK, and everyone starts at the lowest:
- Foundayo 0.8 mg film-coated tablets: the starting dose, taken once daily for at least 30 days.
- Foundayo 2.5 mg film-coated tablets: the second step, again for at least 30 days.
- Foundayo 5.5 mg film-coated tablets: the third step, and the first dose with substantial weight-loss trial data behind it.
- Foundayo 9 mg film-coated tablets, Foundayo 14.5 mg film-coated tablets and Foundayo 17.2 mg film-coated tablets: optional further steps, each after at least 30 days, depending on how well the current dose is working and how well it is tolerated.
17.2 mg is the maximum. Tablets are swallowed whole, never crushed, split or chewed, and two tablets are never taken together to reach a higher dose.
The slow climb exists for tolerability. Nausea, vomiting and diarrhoea are most frequent in the weeks after each increase and ease as the body adjusts. Moving up too quickly is the most common reason people struggle early on. In practice nobody reaches the top dose before roughly month six, and many stay on a lower dose that is already working.
One frequent source of confusion: news coverage of the trials quotes doses of 6 mg, 12 mg and 36 mg. Those were capsules used in research. The UK tablets are absorbed differently, so the numbers differ: the 5.5 mg tablet matches the 6 mg capsule, 9 mg matches 12 mg and 17.2 mg matches 36 mg. They are not interchangeable milligram for milligram.
Some other medicines change how much orforglipron reaches the bloodstream. With strong enzyme blockers such as the antibiotic clarithromycin, the maximum dose drops to 9 mg. St John’s wort and certain epilepsy medicines can make it less effective and are best avoided. People taking simvastatin will usually need that dose halved. A complete medicine list at the consultation is what allows the prescriber to catch these.
Foundayo Side Effects and Who Should Avoid It
Digestive effects dominate. Nausea, constipation, diarrhoea, vomiting, indigestion and stomach pain are all listed as very common, meaning they affect more than 1 in 10 people. In the weight trials, 68.7% of people on the highest dose had at least one digestive side effect, compared with 36.3% on placebo. Most were mild or moderate, and 6.8% stopped treatment because of them.
Common effects, affecting up to 1 in 10, include bloating, burping, reflux, wind, headache, dizziness, tiredness, a faster heart rate, low blood pressure and gallstones. Hair loss was reported by 3.7% of people taking orforglipron for weight management against 1.8% on placebo. It was temporary and linked to the weight loss itself.
Some symptoms need prompt medical attention rather than waiting:
- severe stomach pain that does not settle, sometimes spreading to the back, which can signal pancreatitis
- pain under the right ribs, fever or yellowing skin, which can point to gallbladder problems
- persistent vomiting or diarrhoea, because dehydration can damage the kidneys
- any sudden change in vision, which has been reported rarely with medicines in this class
Anyone due a general anaesthetic or deep sedation should tell the anaesthetist, because slower stomach emptying raises the risk of inhaling stomach contents.
Foundayo is not used in pregnancy or while breastfeeding, and it should be stopped at least three weeks before a planned pregnancy. It may make the contraceptive pill less reliable, so the licence advises switching to a non-oral method or adding condoms for 30 days after starting and for 30 days after every dose increase. It is not recommended for people with severe liver disease, and anyone taking insulin or a sulfonylurea may need those doses reduced.
The Foundayo patient information leaflet on the emc covers all of this in plain language. Suspected side effects can be reported through the MHRA Yellow Card scheme, which matters more than usual for a new medicine under additional monitoring.
Why an Aesthetic Practitioner Needs to Know
Faster weight loss changes the face. Fat pads in the cheeks and temples shrink, folds around the mouth can deepen, and some people notice hair shedding a few months in. A practitioner planning filler, skin boosters or a hair-thinning treatment needs to know a client is mid-course, because results placed during active weight loss can look different once weight settles. Recording the medicine and current dose on the clinic’s digital consent forms gives both client and practitioner a dated record to refer back to, and it brings the sedation and contraception points above into the conversation before they cause a problem.
Foundayo vs Mounjaro: Tablet or Weekly Injection?
Both are made by Eli Lilly, but they are different medicines. The Mounjaro KwikPen contains tirzepatide, which acts on two hormone receptors (GIP and GLP-1) and is injected once a week. The Faces blog explains how the Mounjaro KwikPen works in more detail.
Much of the discussion around the Foundayo weight loss pill UK launch returns to one question: is a tablet as effective as an injection? On current evidence, not quite. In the SURMOUNT-1 trial, people on the top 15 mg dose of tirzepatide lost an average of 20.9% of their body weight over 72 weeks. In ATTAIN-1, the top orforglipron dose produced an average loss of 12.4% over the same period. These were separate trials in different people, so the comparison is a guide rather than a head-to-head result.
What the tablet offers is format. There are no needles, no pens to keep in the fridge and no fixed injection day. For someone who would never start an injection, a medicine they will actually take consistently may serve them better than a stronger one they avoid. Lilly has also said Foundayo’s private price will sit below Mounjaro’s, which is commonly quoted at around £330 a month.
The choice between them belongs to the prescriber, based on BMI, other conditions, current medicines and the person’s own preferences. For a wider look at every licensed option, see this overview of UK weight loss injections and pills.
Foundayo Cost and What a Private Prescription Includes
There is no single Foundayo price in the UK. Lilly indicated at launch that it expected private prices of roughly £100 to £120 a month, but each pharmacy sets its own figure. Advertised prices in October 2026 run from about £95 a month on the starting doses to around £190 on the highest, with subscription discounts common.
Two things explain the spread. The first is dose: most pharmacies keep the first three strengths at one price and charge more from 9 mg upwards. The second is what is included. The Foundayo pill cost quoted by a reputable pharmacy should cover the consultation, review by a registered prescriber, dispensing and delivery. Some providers charge separately for follow-ups or dose changes, so headline prices alone can mislead.
Over a year the gap is significant. At £100 a month, twelve months costs £1,200; at £180, it costs £2,160. Budgeting for the higher doses rather than the introductory price avoids surprises at month four or five. The Faces breakdown of Mounjaro cost per dose shows the same pattern with injections, where the price climbs as the dose does.
For readers asking How much does orforglipron cost? over the longer term, the NHS decision could change the answer. If NICE recommends it in November, eligible patients would pay the standard prescription charge, although NHS access to weight-loss medicines has so far been phased and limited to people with higher BMIs and several related conditions.
The route to avoid is any website that lets people buy Foundayo without a medical questionnaire, identity checks and a prescriber review. The MHRA has acted repeatedly against illegal supplies of weight-loss medicines, including products containing the wrong drug, the wrong dose or contaminants. Listings offering Foundayo pill UK delivery with no consultation are not legitimate pharmacies, however professional the website looks.
Foundayo Reviews: What the Trial Results Show
Personal accounts from people taking it are growing online, but most describe the first few months, when side effects peak and the dose is still low. A more reliable picture comes from the two 72-week weight trials in the ATTAIN programme.
In ATTAIN-1, published in the New England Journal of Medicine, 3,127 adults without diabetes took orforglipron or placebo alongside diet and activity advice. Using the figures in the UK licence, average weight loss was:
- 7.8% on the dose equivalent to the 5.5 mg tablet
- 9.3% on the dose equivalent to 9 mg
- 12.4% on the dose equivalent to 17.2 mg
- 0.9% on placebo
At the top dose, 59.6% of people lost at least 10% of their body weight and around one in five lost 20% or more. Waist measurement fell by an average of 11 cm. Among people who started with prediabetes, 91.3% on the top dose had normal blood sugar by the end, compared with 42.4% on placebo.
ATTAIN-2, in adults with type 2 diabetes, showed a smaller average loss of 10.5% at the top dose. That is typical: weight tends to come off more slowly when diabetes is present.
Two cautions sit beside the headline numbers. Averages hide a wide range, and some people lose very little. Heart rate also rose slightly on treatment, by around 4 to 5 beats per minute at the end of the study, which prescribers keep an eye on. Press reports sometimes quote different percentages, such as 11.2%, because they use a different statistical method. The UK licence figures above are the ones prescribers work from.
The next date to watch is 18 November 2026, when NICE is due to publish its decision on NHS use. Until then, Foundayo remains a private-prescription medicine with a clear licence, a gradual monthly titration and side effects that are heaviest in the early weeks. The most useful habit for anyone starting it is to keep a note of the current dose and the date of each increase, and to share it at every medical and aesthetic appointment, so everyone involved in their care works from the same information.
FAQs
How long does Foundayo take to work?
Changes in appetite are often noticed within the first few weeks, but meaningful weight loss builds over months. Because each dose step lasts at least 30 days, most people are still increasing their dose for the first four to six months, and the main trial results were measured at 72 weeks.
Does Foundayo need to be taken on an empty stomach?
No. The UK licence allows it to be taken at any time of day, with or without food or water. Taking it at the same time each day simply makes it easier to remember.
Can Foundayo stop the contraceptive pill working?
It may make oral contraceptives less reliable. The licence advises switching to a non-oral method, or adding condoms, for 30 days after starting and for 30 days after each dose increase. It should also be stopped at least three weeks before trying to conceive.
What happens if a dose of Foundayo is missed?
The missed dose should be taken as soon as possible, then the usual routine continued. Two tablets should never be taken in one day to catch up. After several missed days, it is sensible to check with the prescriber before carrying on, as they may advise on whether to continue at the same dose.
Should an aesthetic practitioner be told about Foundayo?
Yes. Weight loss changes facial volume and can cause temporary hair shedding, which affects the timing and outcome of treatments such as filler. The medicine also matters for any procedure involving sedation. Listing it on the medical history and consent form, with the current dose, keeps the clinic’s record accurate.
Your clients are asking about weight loss pills. Be ready.
Register with Faces Pharmacy now and start ordering Foundayo tablets as soon as you’re approved. Our simple online ordering and reliable delivery make it easy to keep stock on hand for your clinic. Join the practitioners already offering Foundayo and meet growing client demand with confidence.